-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our target at $84, 20.1x our 2027 EPS estimate, in line with CVTA's five-year average. After Q1 earnings release, we raise our 2026 EPS view to $4.01 from $3.72 to reflect the Q1 beat. We maintain our 2027 EPS estimate at $4.17. CTVA delivered strong Q1 2026 results today after market close, demonstrating robust operational execution across both business segments, while maintaining momentum toward the planned 2H 2026 separation of the Seed and Crop Protection business. Net sales increased to $4.9B (+11% Y/Y) with organic growth of 7% Y/Y, reflecting broad-based demand for the company's differentiated technology offerings across all geographic regions. Management confirmed the separation remains on track for 2H 2026, with key milestones including Luke Kissam's appointment as New Corteva CEO and the announcement of "Vylor" as the future seed and genetics company name. Yet, with shares up nearly 32% in the last six months, we see limited upside potential at this point and lower our rating to Hold from Buy.